Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTD1801 in NASH with liver fibrosis and type 2 diabetes or prediabetes
CTR20234120Phase 2Completed
- Sponsor
- HighTide Therapeutics, Inc.
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of berberine ursodeoxycholate in metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes mellitus (T2DM), prediabetes, sponsored by HighTide Therapeutics, Inc.. Started Dec 2023; status: completed.
02
Drugs
berberine ursodeoxycholate
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)type 2 diabetes mellitus (T2DM)prediabetes
Beyond the preview
Go deeper on CTR20234120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234120.